Asan Medical Center | Clinical Trial Center
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria :
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
466 participants in 4 patient groups
Loading...
Central trial contact
Study Director, MD; BeiGene
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal